G003762

HPLC Analysis of Piroxicam and 2-Aminopyridine in Urine on Discovery^® HS F5 after SPE using Discovery^® DSC-MCAX

application for SPE, application for HPLC

Properties

• technique(s): HPLC: suitable; solid phase extraction (SPE): suitable
• test parameters: sample preparation: SPE (Solid Phase Extraction); sample/matrix: human urine spiked with piroxicam (4 μg/mL) and 2-aminopyridine (10 μg/mL); SPE tube/cartridge: Discovery DSC-MCAX, 100 mg/3 mL (52783-U); condition: 1 mL methanol; 1 mL 10 mM potassium phosphate, pH 3; sample addition: 1 mL; washing: 1 mL 10 mM potassium phosphate, pH 3; 1 mL methanol; elution: 1 mL 5% ammonium hydroxide in methanol; eluate post-treatment: evaporate to dryness with nitrogen at room temperature, reconstitute in 1 mL mobile phase; column: Discovery HS F5, 15 cm x 4.6 mm I.D., 5 μm particles (567516-U); mobile phase: [A] 10 mM potassium phosphate, pH 6: [B] acetonitrile (85:15, A:B); flow rate: 2 mL/min; column temp.: 25 °C; detector: UV, 220 nm; injection: 10 μL
• suitability: application for HPLC; application for SPE
• application(s): clinical

Description

Application

Sample Pre-Treatment:
Piroxicam and 2-aminopyridine (piroxicam′s polar metabolite) was spiked into human urine at the levels of 4 and 10 μg/mL, respectively. The urine sample was diluted 1:1 with 10 mM potassium phosphate, pH 3.

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany